Novo Nordisk Kalundborg >42 bn DKK Nov 2023, Hillerød 15.9 bn DKK API + 2.9 bn DKK QC lab, Bavarian Nordic Kvistgaard, Lundbeck Valby.
Cross-border cleanroom pharma fit-out workforce mobilisation against Novo Nordisk Kalundborg API expansion (announced November 2023; >42 bn DKK investment; phased completion end-2025 → 2029; multi-product API supporting GLP-1 portfolio; 800 permanent jobs + up to 3,000 construction workforce during build), Novo Nordisk Hillerød Multi-Product API + QC Lab (15.9 bn DKK / ~$2.3 bn API facility ~700,000 sq ft API production target 2029 + 2.9 bn DKK / ~$409 m QC laboratory 53,000 m² completion 2027), Bavarian Nordic Kvistgaard (Hejreskovvej; commercial-scale multi-product fill-and-finish line for liquid + freeze-dried live viral vaccines; prior $75 m fill/finish + cleanroom suite addition; located 40 km north of Copenhagen), and Lundbeck Valby Copenhagen (HQ + drug-product manufacturing; ~1.5 bn DKK committed to Danish site modernisation through 2025) — Lægemiddelstyrelsen (Danish Medicines Agency) + EU GMP Annex 1 (2022 mandatory 25 August 2023).
Request Technical BriefingRegulator exposure profile
- Lægemiddelstyrelsen + EU GMP Annex 1 202228%
- ICH Q9(R1) CCS22%
- 3F Industri overenskomst + Bygge- og anlæg26%
- RUT register + Lov 566/202224%
Grade A aseptic processing positive-pressure cascade.
Novo Nordisk Kalundborg + Hillerød + Bavarian Nordic Kvistgaard cleanroom fit-outs ladder GMP Grade A → D against EU GMP Annex 1 (2022 mandatory 25 August 2023) + ISO 14644-1:2015 + Lægemiddelstyrelsen inspectorate + ICH Q9(R1) CCS approach.
▲ Grade A · aseptic processing
- Grade A fulfilled
Aseptic processing
- +30 Pa
- ISO Class 5 in-operation
- microbial < 1 CFU/m³
- Grade B fulfilled
Background to Grade A
- +15 Pa
- ISO Class 7 in-operation
- Grade C partial
Clean prep / formulation
- +5 Pa
- ISO Class 8 in-operation
- Grade D unfulfilled
Less critical stages
- Background
- AT-vejledninger
▼ Grade D · background
Named projects in this jurisdiction
- Novo Nordisk Kalundborg API expansion (announced November 2023; >42 bn DKK investment; phased completion end-2025 → 2029; multi-product API facility supporting GLP-1 portfolio; 800 permanent jobs + up to 3,000 construction workforce during build) Novo Nordisk A/S 2023
- Novo Nordisk Hillerød Multi-Product API + QC Lab (15.9 bn DKK / ~$2.3 bn multi-product API facility ~700,000 sq ft target 2029; 2.9 bn DKK / ~$409 m QC laboratory 53,000 m² completion 2027) Novo Nordisk A/S
- Bavarian Nordic Kvistgaard / Hejreskovvej (commercial-scale multi-product fill-and-finish line for liquid + freeze-dried live viral vaccines; prior $75 m fill/finish + cleanroom suite addition; 40 km north of Copenhagen) Bavarian Nordic A/S
- Lundbeck Valby Copenhagen (HQ + drug-product manufacturing; ~1.5 bn DKK committed to Danish site modernisation through 2025; full-value-chain R&D + DP manufacturing co-located) H. Lundbeck A/S
Denmark’s pharma fit-out anchor in 2026 is Novo Nordisk Kalundborg (>42 bn DKK announced Nov 2023; phased 2025-2029) + Hillerød (15.9 bn DKK API + 2.9 bn DKK QC lab) + Bavarian Nordic Kvistgaard + Lundbeck Valby. Lægemiddelstyrelsen holds GMP authority; EU GMP Annex 1 (2022) mandatory since 25 Aug 2023.
01. Pre-pricing — 3F Industri + Bygge- og anlæg
Construction + cleanroom-fit-out workforce under 3F Industri overenskomst + 3F Bygge- og anlæg overenskomst. Denmark-bank-traceable remuneration mandatory.
02. A1 + Danish-language contract + EU GMP Annex 1 competency
A1 + Danish-language contract predate site arrival. EU GMP Annex 1 (2022) competency per cleanroom worker. ISO 14644-1:2015 classification per zone.
03. Lægemiddelstyrelsen + Novo / Bavarian Nordic onboarding
Lægemiddelstyrelsen manufacturing-authorisation reconciliation. Novo Nordisk / Bavarian Nordic / Lundbeck operator-specific cleanroom-gowning qualification per worker.
04. Arbejdstilsynet + Lægemiddelstyrelsen-defensible evidence pack
Minimum pack: Denmark-bank-traceable remuneration, Danish-language contract, A1 receipt, 3F overenskomst tariff reconciliation, gowning record per cleanroom worker.
05. India and Gulf sourcing corridors — the Denmark pharma pathway
Indian pharma-trade pools through Cipla + Sun Pharma + Dr. Reddy”s cleanroom-equipment trade. The 8 to 14-week corridor delivers Grade-A-eligible candidates against Novo Nordisk Kalundborg expansion, Hillerød, Bavarian Nordic, or Lundbeck Valby.